Advertisement
Neuroscience perspectives| Volume 56, ISSUE 11, P819-824, December 01, 2004

Cytokines and psychopathology: Lessons from interferon-α

  • Lucile Capuron
    Affiliations
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
    Search for articles by this author
  • Andrew H. Miller
    Correspondence
    Address reprint requests to Andrew H. Miller, M.D., Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Drive, Suite 4000, Atlanta, GA 30322, USA
    Affiliations
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA
    Search for articles by this author

      Abstract

      Interferon-α is a potent inducer of the cytokine network and is notorious for causing behavioral alterations. Studies on interferon-α-treated patients reveal at least two distinct syndromes: 1) a mood/cognitive syndrome that appears late during interferon-α therapy is responsive to antidepressants and is associated with activation of neuroendocrine pathways and altered serotonin metabolism; and 2) a neurovegetative syndrome characterized by psychomotor slowing, and fatigue that appears early during interferon-α treatment is antidepressant nonresponsive and may be mediated by alterations in basal ganglia dopamine metabolism. Findings from interferon-α may provide important clues regarding the pathophysiology and treatment of cytokine-induced behavioral changes in medically ill patients, while also potentially modeling the development of neuropsychiatric symptoms in patients without medical disorders.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Berger J.R.
        • Arendt G.
        HIV dementia.
        J Psychopharmacol. 2000; 14: 214-221
        • Besedovsky H.O.
        • del Rey A.
        Immune-neuro-endocrine interactions.
        Endocr Rev. 1996; 17: 64-102
        • Bower J.E.
        • Ganz P.A.
        • Aziz N.
        • Fahey J.L.
        Fatigue and proinflammatory cytokine activity in breast cancer survivor.
        Psychosom Med. 2002; 64: 604-611
        • Capuron L.
        • Gumnick J.F.
        • Musselman D.L.
        • Lawson D.H.
        • Reemsnyder A.
        • Nemeroff C.B.
        • et al.
        Neurobehavioral effects of interferon-alpha in cancer patients.
        Neuropsychopharmacology. 2002; 26: 643-652
        • Capuron L.
        • Neurauter G.
        • Lawson D.H.
        • Musselman D.L.
        • Nemeroff C.B.
        • Fuchs D.
        • et al.
        Interferon-alpha-induced changes in tryptophan metabolism.
        Biol Psychiatry. 2003; 54: 906-914
        • Capuron L.
        • Pagnoni G.
        • Lawson D.H.
        • Demetrashvili M.
        • Woolwine B.J.
        • Kilts C.D.
        • et al.
        Altered fronto-pallidal activity during high-dose interferon-alpha treatment as determined by positron emission tomography.
        Abstr Soc Neurosci. 2002; 498: 5
        • Capuron L.
        • Raison C.L.
        • Musselman D.L.
        • Lawson D.H.
        • Nemeroff C.B.
        • Miller A.H.
        Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
        Am J Psychiatry. 2003; 160: 1342-1345
        • Cleeland C.S.
        • Bennett G.J.
        • Dantzer R.
        • Dougherty P.M.
        • Dunn A.J.
        • Meyers C.A.
        • et al.
        Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms.
        Cancer. 2003; 97: 2919-2925
        • Dantzer R.
        • Wollman E.E.
        • Yirmiya R.
        Cytokines, Stress, and Depression.
        Plenum, Kluwer Academic, New York1999
        • Delgado P.L.
        • Charney D.S.
        • Price L.H.
        • Aghajanian G.K.
        • Landis H.
        • Heninger G.R.
        Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.
        Arch Gen Psychiatry. 1990; 47: 411-418
        • Evans D.L.
        • Staab J.P.
        • Petitto J.M.
        • Morrison M.F.
        • Szuba M.P.
        • Ward H.E.
        • et al.
        Depression in the medical setting.
        J Clin Psychiatry. 1999; 60: 40-56
        • Gao H.M.
        • Jiang J.
        • Wilson B.
        • Zhang W.
        • Hong J.S.
        • Liu B.
        Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons.
        J Neurochem. 2002; 81: 1285-1297
        • Greenberg D.B.
        • Gray J.L.
        • Mannix C.M.
        • Eisenthal S.
        • Carey M.
        Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer.
        J Pain Symptom Manage. 1993; 8: 196-200
        • Haas H.S.
        • Schauenstein K.
        Neuroimmunomodulation via limbic structures.
        Prog Neurobiol. 1997; 51: 195-222
        • Heim C.
        • Newport D.J.
        • Heit S.
        • Graham Y.P.
        • Wilcox M.
        • Bonsall R.
        • et al.
        Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood.
        JAMA. 2000; 284: 592-597
        • Holsboer F.
        The corticosteroid receptor hypothesis of depression.
        Neuropsychopharmacology. 2000; 23: 477-501
        • Juengling F.D.
        • Ebert D.
        • Gut O.
        • Engelbrecht M.A.
        • Rasenack J.
        • Nitzsche E.U.
        • et al.
        Prefrontal cortical hypometabolism during low-dose interferon alpha treatment.
        Psychopharmacology (Berl). 2000; 152: 383-389
        • Kamata M.
        • Higuchi H.
        • Yoshimoto M.
        • Yoshida K.
        • Shimizu T.
        Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain.
        Eur Neuropsychopharmacol. 2000; 10: 129-132
        • Konsman J.P.
        • Parnet P.
        • Dantzer R.
        Cytokine-induced sickness behavior.
        Trends Neurosci. 2002; 25: 154-159
        • Lou J.S.
        • Kearns G.
        • Benice T.
        • Oken B.
        • Sexton G.
        • Nutt J.
        Levodopa improves physical fatigue in Parkinson’s disease.
        Mov Disord. 2003; 18: 1108-1114
        • Maes M.
        Major depression and activation of the inflammatory response system.
        Adv Exp Med Biol. 1999; 461: 25-46
        • Martinot M.
        • Bragulat V.
        • Artiges E.
        • Dolle F.
        • Hinnen F.
        • Jouvent R.
        • et al.
        Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation.
        Am J Psychiatry. 2001; 158: 314-316
        • Mellor A.L.
        • Munn D.H.
        Tryptophan catabolism and T-cell tolerance.
        Immunol Today. 1999; 20: 469-473
        • Morrow G.R.
        • Hickok J.T.
        • Roscoe J.A.
        • Raubertas R.F.
        • Andrews P.L.
        • Flynn P.J.
        • et al.
        Differential effects of paroxetine on fatigue and depression.
        J Clin Oncol. 2003; 21: 4635-4641
        • Musselman D.L.
        • Lawson D.H.
        • Gumnick J.F.
        • Manatunga A.K.
        • Penna S.
        • Goodkin R.S.
        • et al.
        Paroxetine for the prevention of depression induced by high-dose interferon alfa.
        N Engl J Med. 2001; 344: 961-966
        • Musselman D.L.
        • Miller A.H.
        • Porter M.R.
        • Manatunga A.K.
        • Gao F.
        • Penna S.
        • et al.
        Higher than normal plasma interleukin-6 concentrations in cancer patients with depression.
        Am J Psychiatry. 2001; 158: 1252-1257
        • Owens M.J.
        • Nemeroff C.B.
        The role of corticotropin-releasing-factor in the pathophysiology of affective and anxiety disorders.
        Ciba Found Symp. 1993; 172: 296-308
        • Raber J.
        • Koob G.F.
        • Bloom F.E.
        Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala.
        Neurochem Int. 1997; 30: 455-463
        • Raison C.L.
        • Miller A.H.
        Depression in cancer.
        Biol Psychiatry. 2003; 54: 283-294
        • Reichenberg A.
        • Kraus T.
        • Haack M.
        • Schuld A.
        • Pollmacher T.
        • Yirmiya R.
        Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion.
        Psychoneuroendocrinology. 2002; 27: 945-956
        • Rye D.B.
        • Jankovic J.
        Emerging views of dopamine in modulating sleep/wake state from an unlikely source.
        Neurology. 2002; 58: 341-346
        • Shuto H.
        • Kataoka Y.
        • Horikawa T.
        • Fujihara N.
        • Oishi R.
        Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain.
        Brain Res. 1997; 747: 348-351
        • Spath-Schwalbe E.
        • Hansen K.
        • Schmidt F.
        • Schrezenmeier H.
        • Marshall L.
        • Burger K.
        • et al.
        Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men.
        J Clin Endocrinol Metab. 1998; 83: 1573-1579
        • Sunami M.
        • Nishikawa T.
        • Yorogi A.
        • Shimoda M.
        Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.
        Clin Neuropharmacol. 2000; 23: 59-61
        • Taylor J.L.
        • Grossberg S.E.
        The effects of interferon-alpha on the production and action of other cytokines.
        Semin Oncol. 1998; 25: 23-29
        • Yamano M.
        • Yuki H.
        • Yasuda S.
        • Miyata K.
        Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.
        J Pharmacol Exp Ther. 2000; 292: 181-187